2021

Hologic Launches Novodiag® System for On-Demand Molecular Testing in Europe 

Launch brings Novodiag’s benefits to broader range of European customers and expands Hologic’s offering of world-leading molecular scalable solutions 

Manchester, UK, October 5, 2021 – Hologic, Inc. (Nasdaq: HOLX) today announced its broad European launch of the Novodiag® system, a fully automated molecular diagnostic solution for on-demand testing of infectious diseases and antimicrobial resistance. The launch follows Hologic’s acquisition of Mobidiag Oy in June 2021 and will bring the benefits of the Novodiag system to a broader range of customers in Europe. 

See poster

Hologic closes acquisition of Mobidiag

June 17, 2021
MARLBOROUGH, Mass.–(BUSINESS WIRE)– Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately $808 million.

“Closing the acquisition of Mobidiag enables us to become a broader, more diversified global diagnostics leader,” said Jan Verstreken, group president, international at Hologic. “Together, we can accelerate development and adoption of Mobidiag’s innovative products globally and drive Hologic’s growth.”

See poster

Mobidiag to Be Acquired by Hologic, Innovator in Women’s Health Diagnostic Testing, for Approximately €668 Million

Transaction Will Accelerate Global Growth of Mobidiag’s Differentiated Molecular Platform, which Offers Ease of Use, Multiplex Capability and Rapid Turnaround Time —

ESPOO, Finland, April 08, 2021 — Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, for an enterprise value of approximately €668 million ($795 million).  This includes a cash payment of approximately €600 million ($714 million) for Mobidiag’s equity, and net debt of approximately €68 million ($81 million).

See poster
Combo respiratory tests Resp-4

Mobidiag receives CE-IVD for Amplidiag® RESP-4 for simultaneous detection of COVID-19, Flu A, Flu B and RSV

  • Real-time PCR-based test enables high-throughput reliable detection of most prevalent respiratory infections, including COVID-19
  • One single test determines the virus responsible for patient symptoms, guiding treatment decisions and rapid isolation strategy if required

FINLAND, Espoo, March 1st, 2021 – Mobidiag Ltd. today announces that it has received CE-IVD marking for its Amplidiag® RESP-4 molecular diagnostic test for the rapid and simultaneous detection of some of the most prevalent respiratory viruses: SARS-CoV-2 (responsible for COVID-19 infection), Influenza A, Influenza B and RSV.

These viruses present similar symptoms, making it difficult for physicians to determine accurately which virus a patient has. The See poster

Amplidiag® and Novodiag® solutions now available through distribution in Norway

Mobidiag Ltd. today announces that it has signed an agreement with XboXLab for the distribution of its molecular diagnostic products Amplidiag® and Novodiag® in Norway.

We are very pleased to expand our distribution network and be able to provide Norwegian clinical laboratories with our innovative molecular diagnostic solutions.

For more information, please contact :
Henning Jansen
+47 40 33 00 11
henning.jansen@xboxlab.no
www.xboxlab.se

Mobidiag products are also available throughout Europe and the Middle East. Visit our See poster

Coronavirus COVID-19

Mobidiag COVID-19 test performances not affected by variants from United Kingdom, South Africa or Brazil

2020 was an unprecedented year as the world faced the unexpected and rapid spread of coronavirus. As the pandemic extends into 2021, we have been witnessing specific new variants spreading rapidly in the United Kingdom, South Africa and Brazil.

These new variants will however not impact the performance of our molecular assays Amplidiag COVID-19, nor Novodiag COVID-19, which utilise targets for N gene and Orf1ab. The new coronavirus variants potentially have an impact on assays using the S protein as a target, which is not the case for Mobidiag tests. At Mobidiag, it is part of our routine post-market surveillance to monitor for new coronavirus variants and developments to ensure that the performance of our assays is always suitable for the market

See poster
2020

Mobidiag Receives Second Tranche of €25M Financing from European Investment Bank

  • Second tranche of €10M from €25M growth capital loan signed with the European Investment Bank in May 2019
  • New funds will be used to accelerate the development, manufacturing and commercialisation of in vitro diagnostics for infectious diseases

    • See poster

    Mobidiag offers complete diagnostic solution for the detection of novel coronavirus infections with both PCR and antibody tests

  • CE-IVD marked molecular diagnostic tests on the Novodiag and Amplidiag platforms for rapid detection of COVID-19 infections to support decisions for efficient patient isolation, treatment and release
  • Antibody test for detection of past COVID-19 infections
  • Secure supply chain and in-house manufacturing capabilities to meet demand

    • See poster
    Molecular diagnostics of coronavirus infection with Novodiag

    Novodiag® COVID-19, a fully automated molecular diagnostic test, granted emergency use authorization in Finland for novel coronavirus

  • Real-time RT-PCR-based test enables fast, on demand and fully automated detection of early COVID-19 infections for rapid isolation and treatment guidance;
  • provides safety for users with a closed system;
  • easy to use with no need for highly trained personnel enabling decentralized testing.

    • See poster
    Molecular diagnostics of coronavirus infection with Amplidiag

    Amplidiag® COVID-19 molecular diagnostic test granted emergency use authorization in Finland for novel coronavirus

    – Real-time PCR-based test enables high-throughput reliable detection of early COVID-19 infections for rapid isolation and treatment guidance

    – Currently set up for routine use in main Finnish clinical labs with capacity to test up to 4,000 samples per day

    Mobidiag Ltd. announces that it has received emergency use authorization in Finland for its Amplidiag® COVID-19 molecular diagnostic test for the rapid detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19). The Amplidiag® COVID-19 is now available for use in Finland*. The test will be run for routine use at the main clinical laboratories in Finland (Helsinki University Hospital (Huslab), SYNLAB and Mehiläinen) doubling Finnish testing capacity and allowing testing coverage for most of the country. The process for obtaining emergency use authorization is now ongoing in Sweden, UK and France. Mobidiag w

    See poster
    Next Page »